Clifford Chance has advised the joint sponsors Goldman Sachs, CICC, Morgan Stanley and GF Capital and the underwriters. Ashurst Perkins Coie has advised Oaktree Capital Management,...
Zhongji Innolight Raises US$7 Billion in Landmark Hong Kong IPO
RIGOL Technologies Secures HK$1.14 Billion in Global Hong Kong IPO
Ashurst and Perkins Coie have advised the underwriters on RIGOL Technologies Co., Ltd’s global offering and listing of H shares on the Main Board of The...
Oaktree Capital Invests as Cornerstone Investor in Momenta Global IPO on Hong Kong Exchange
Ashurst Perkins Coie has advised Oaktree Capital Management on its US$20 million cornerstone investment in Momenta Global Limited. Oaktree Capital Management, L.P. participated as a cornerstone...
KV Asia Capital and Consortium Acquire Stake in i-Sprint Innovations
Ashurst ADTLaw has advised KV Asia Capital on its acquisition of a stake in i-Sprint Innovations. KV Asia Capital Pte. Ltd., together with a consortium of...
Hanx Biopharmaceuticals Completes HK$586 Million Hong Kong IPO
Ashurst has advised ICBC International Capital Limited. Hanx Biopharmaceuticals (Wuhan) Co., Ltd., a China-based biopharmaceutical company, has successfully completed a global offering amounting to HK$586.3 million,...
Xizang Zhihui Mining Raises $550 Million in Hong Kong IPO
Ashurst has advised Xizang Zhihui Mining Co., Ltd. Xizang Zhihui Mining Co., Ltd. (SEHK: 2546) has completed a global offering and listed its shares on the...
Butong Group Completes HK$781.84 Million Hong Kong IPO
Ashurst has advised the underwriters of Butong Group. Butong Group has completed its global offering and successfully listed its shares on the Main Board of The...
Meta-Wisdom Acquires Controlling Stake in Home Control Through Mandatory Cash Offer
Ashurst has advised Home Control International Limited. Home Control International Limited (SEHK: 1747) was the subject of a mandatory unconditional general cash offer for all its...
Cloudbreak Pharma Launches Successful IPO on Hong Kong Stock Exchange
Ashurst has advised the joint sponsors and underwriters on Cloudbreak Pharma’s global offering and Hong Kong listing. Cloudbreak Pharma Inc., a clinical-stage biotechnology company, successfully completed...
SeaTown Private Capital Master Fund’s $40 Million Investment In Linnovate Partners Group Ltd
Ashurst represented SeaTown Private Capital Master Fund. SeaTown Private Capital Master Fund has completed its USD 40 million funding commitment to Linnovate Partners Group Limited. SeaTown...
China Qidian Guofeng Holdings Limited’s Agreement With Noble Trade International Holdings Ltd
Ashurst acted for China Qidian Guofeng Holdings Limited on the deal. China Qidian Guofeng Holdings Limited subscribed an agreement with Noble Trade International Holdings Limited. Under...
Adtiger Corporations Limited’s HK$13 Million Share Placement
Ashurst advised Adtiger Corporations Limited on the deal. Adtiger Corporations Limited completed the placing and subscription agreement with Kam Luen Securities Limited, on the the Placing of...